(CercleFinance.com) – Novartis announced Tuesday evening that it had implemented a series of measures intended to meet new regulatory standards surrounding early-stage breast cancer treatments.
The biopharmaceutical group indicates that it has made changes to its manufacturing activities in this area, with the objective of complying with these new standards by the end of June.
These modifications come following recent changes in regulation, which provide for a limitation of the presence of nitrosamines, potentially carcinogenic compounds, in medicines for human use.
If Novartis specifies that these measures do not affect the use of Kisqali in the already approved indication of metastatic breast cancer, the Basel laboratory emphasizes having suspended the recruitment of patients in clinical trials which relate to its effectiveness in breast cancer. early breast.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
